Charles River Labs Intl Stock
Charles River Labs Intl Stock
Pros and Cons of Charles River Labs Intl in the next few years
Pros
Cons
Performance of Charles River Labs Intl vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Charles River Labs Intl | -0.580% | -2.248% | -8.722% | 4.429% | -8.122% | -28.577% | - |
Ironwood Pharmaceuticals | 5.450% | 6.422% | -24.675% | -43.137% | -43.137% | -38.947% | - |
Novocure Ltd | -0.580% | -4.920% | 53.480% | -72.684% | 42.137% | -87.762% | - |
Iovance Biotherapeutics Inc. | -0.550% | -11.212% | -31.823% | -0.317% | 4.867% | -45.322% | - |
Comments
News
Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the introduction of its Modular and Fast Track viral vector technology (tech) transfer frameworks. Based on decades of
Charles River Laboratories Announces First-Quarter 2024 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.7% from $1.03
Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, designed to